| ID | 10087 |
| Vaccine Name | CYD-TDV Dengvaxia |
| Disease Name | Dengue fever |
| Disease Classification | Hemorrhagic |
| Virus Name | Dengue virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Live-attenuated |
| Vaccine Status | Approved |
| Manufacturer | Sanofi Pasteur |
| Year of Manufacturing | 2015 |
| Manufacturing Country | France |
| Age | 9 - 45 years |
| Dosage | 3 doses 6 months apart |
| Administration Route | Subcutaneous |
| Adjuvant | NA |
| Target Strain | Dengue virus serotypes (1, 2, 3 and 4) |
| Description | 17D vaccine vector expressing genes of DENV-1, 2, 3, or 4 |
| Approving Organisation | US FDA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | NA |
| PMID | 30684747 |
| Clinical Trial ID | NCT02747927 |
| Reference Link | https://www.sciencedirect.com/science/article/pii/S1201971219300402 |
| Additional Links | https://www.fda.gov/media/124379/download
|